## TEM: Tempus AI, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -6.9% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($60.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Tempus AI price target lowered to $80 from $85 at JPMorgan**
- Source: TipRanks | 20251215T150933 | Bearish | Relevance: 100%
- JPMorgan analyst Casey Woodring has lowered the price target for Tempus AI (TEM) to $80 from $85 while maintaining a Neutral rating on the shares. This adjustment reflects updated models within the life science tools and diagnostics sector.

**2. Tempus AI price target lowered to $80 from $90 at BofA**
- Source: Yahoo Finance | 20251216T160921 | Somewhat-Bearish | Relevance: 100%
- BofA analyst Michael Ryskin has lowered the price target for Tempus AI (TEM) to $80 from $90, while maintaining a Neutral rating. The adjustment is part of a firm-wide update for Life Sciences & Diagnostic Tools stocks, anticipating a market normalization and a return to spending by Biopharma in 2026. BofA favors companies with higher exposure to research and development.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | JP Morgan | $80 | $85 | -6% |
| 2025-12-02 | Morgan Stanley | $85 | $80 | +6% |
| 2025-11-25 | BTIG | $105 | $96 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | JP Morgan | main | Neutral |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-25 | BTIG | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 5.7% (+106.8%)
- BAILLIE GIFFORD & CO: 5.6% (-19.9%)
- Vanguard Group Inc: 5.5% (+22.1%)
- ARK Investment Manag: 4.2% (-3.3%)
- Blackrock Inc.: 3.9% (+62.8%)

### Key Risks

1. High beta (2.92) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-7.4% 5d) with bearish MACD, trend may be turning.
3. High short interest (15.1%, 3.3 days to cover): squeeze risk or crowded bearish bet.
4. Near-term weakness: 15.2% below SMA50 despite long-term uptrend.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.49 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.3x). Revenue growth strong at 25% YoY. Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.1B |
| Beta | 1.00 |
| 52W Range | $31.36 - $104.32 |
| Short Interest | 15.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.49 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 0.6% to -6.9% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.9pp (needs >4.0% for momentum thesis). AM_20 at -7.0% indicates price below own 20MA trend. Underperforming sector by 6.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.87% (CS: 6) | Weak |
| RSI_14 | 35.6 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.930x | Below |
| vs SMA50 | 0.848x | Below |
| vs SMA200 | 1.016x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $68.11
- **Stop Loss:** $60.57 (11.1% risk)
- **Target:** $75.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $8,990.52
- **Portfolio %:** 8.99%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-24 (Est: $-0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.18 | $-0.11 | +37.3% |
| 2025Q2 | $-0.25 | $-0.22 | +13.0% |
| 2025Q1 | $-0.27 | $-0.24 | +10.2% |
| 2024Q4 | $-0.15 | $-0.18 | -17.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*